Abstract
ObjectiveCholinesterase inhibitors (ChEIs) and memantine are the only approved pharmacological treatments for Alzheimer’s disease (AD). Recent literature suggests reductions in cardiovascular burden and risk of stroke in ChEI users. However,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have